Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Late annual account NBB
Fiscal year 2024 was filed 476 days after the legal deadline.
Financials
Financial year 2024
PharmaLex Belgium from Zaventem, company number BE0667829063, closed financial year 2024 with a result of € -102,323 after tax. For that financial year PharmaLex Belgium recorded revenue of € 8.4 million and equity of € 2.4 million. Compared with financial year 2023, the result moved from € 577,668 to € -102,323. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 19, 2026.
€ 2.4 million
▼ 4% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -102,323
▼ still € 577,668 profit in 2023
Profit after tax over the fiscal year.
€ 1.1 million
▼ 45% vs 2023
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 2.2 million.
People and assets in 2024
47.1
▼ 2.9 vs 2023
Average over the fiscal year, from the social balance sheet.
€ 4.7 million
▲ 19% vs 2023
€ 100,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 107,157
▲ 51% vs 2023
Of which on lease € 3,448.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 892,742
▼ 5% vs 2023
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 84 days on average.
€ 806,194
▼ 52% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Revenue | € 4,637,220 | € 5,736,800 | € 6,993,437 | € 8,370,817 | ▲ 20% |
| Gross margin | € 2,849,403 | € 3,478,095 | - | - | |
| Profit after taxes | € 419,825 | € 559,419 | € 577,668 | € -102,323 | ▼ € 679,991 |
| Equity | € 926,251 | € 1,335,670 | € 2,461,420 | € 2,359,097 | ▼ 4% |
| Total debts | € 1,701,611 | € 2,377,180 | € 3,334,192 | € 2,539,376 | ▼ 24% |
| Cash | € 173,617 | € 399,948 | € 1,922,780 | € 1,066,696 | ▼ 45% |
| Retained profit | € 826,251 | € 1,235,670 | € 2,342,820 | € 2,240,497 | ▼ 4% |
| Dividend | € 100,000 | € 150,000 | € 0 | € 0 | |
| Bank debt | € 5,491 | € 2,591 | € 0 | € 0 | |
| Balance sheet total | € 2,627,862 | € 3,712,850 | € 5,871,467 | € 4,974,328 | ▼ 15% |
| Employees (FTE) | 25.6 | 28.5 | 50 | 47.1 | ▼ 2.9 |
Key figures of PharmaLex Belgium, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 30 April 2026.
What happened to PharmaLex Belgium?
What happened at PharmaLex Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Anne Peeters stepped down as director. NBB
- Christopher Gauglitz stepped down as director. NBB
- Pharmalex France SAS stepped down as director. NBB
- New annual accounts for financial year 2024: loss of € 102,323 (▼ € 679,991 vs 2023). filed late Source: NBB ↗
- Anne Peeters became a director. NBB
- Christopher Gauglitz became a director. NBB
- Pharmalex France SAS became a director. NBB
- New establishment in Zaventem. KBO
In short
From € 419,825 profit in 2021 to € 102,323 loss in 2024.
Paid € 539,676 in corporate taxes since 2021.
Best year ever: 2023, with € 577,668 profit.
On average € 122,000 of value added per employee in 2022.
A new publication or filing at PharmaLex Belgium? We notify you, reason included.
Follow PharmaLex BelgiumDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The shares are held by AmerisourceBergen International B.V. (100%).
Directors
According to the 2024 annual accounts
Anne Peeters
Director
since 2024 · until 2030
Christopher Gauglitz
Director
since 2024 · until 2030
Pharmalex France SAS
Director · represented by Åsa Pihlblad
since 2024 · until 2030
Shareholders
AmerisourceBergen International B.V.
100%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Weiveldlaan 3 box 5
1930 Zaventem
Rue Edouard Belin 5
1435 Mont-Saint-Guibert
Active since 19 December 2016
Weiveldlaan 3/5
1930 Zaventem
Active since 1 August 2023
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0667.829.063
- VAT number
- BE 0667.829.063
- Registered office
- Weiveldlaan 3 bus 5, 1930 Zaventem
- Names & denominations
- PharmaLex Belgium
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 19 December 2016
- Peppol
- Active · Active since 10 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering
Overige dienstverlenende activiteiten op het gebied van informatie
Overige dienstverlenende activiteiten op het gebied van informatie, n.e. g.